Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Rohto Pharmaceutical Co ( (JP:4527) ) has provided an update.
Rohto Pharmaceutical Co., Ltd. reported its consolidated financial results for the third quarter of the fiscal year ending March 31, 2025, showing a 12.3% increase in net sales year-on-year but a decline in operating and ordinary income by 8.5% and 10.4%, respectively. Notably, the company’s capital adequacy ratio dropped from 71.0% to 63.3%, reflecting changes in financial position and strategic consolidations, which included the addition of several new subsidiaries. The company’s financial forecast for the full fiscal year remains unchanged, projecting a net income per share of 141.14 yen, highlighting its commitment to achieving steady growth despite potential challenges in the market.
More about Rohto Pharmaceutical Co
Rohto Pharmaceutical Co., Ltd. is a company listed on the Tokyo Stock Exchange, engaged in the pharmaceutical industry. They primarily focus on the production and sale of pharmaceutical products and services, with a strong market presence in Japan and international markets.
YTD Price Performance: -10.18%
Average Trading Volume: 5,490
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.72B
For detailed information about 4527 stock, go to TipRanks’ Stock Analysis page.